Online inquiry

IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1550MR)

This product GTTS-WQ1550MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets BMP10&GDF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014482.3; NM_016204.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27302; 2658
UniProt ID O95393; Q9UK05
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1550MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5095MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ239MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ9716MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ8750MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ7237MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ2246MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ15163MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ12592MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW